Summary
There are 500,000 persons with dementia living in Canada. Up to 75% of persons with dementia experience neuropsychiatric symptoms (e.g. agitation, aggression, and depression). Neuropsychiatric symptoms are associated with adverse outcomes including functional decline, earlier nursing home admission, and caregiver burden. Although neuropsychiatric symptoms are common, there are important knowledge gaps in how we detect and treat these symptoms, which creates uncertainty in medical decision-making and practice variation among clinicians. For example, prescribing trends suggest clinicians are increasingly prescribing medications other than antipsychotics (e.g. trazodone) to reduce neuropsychiatric symptoms in persons with dementia. However, we have less evidence supporting the efficacious and safe use of these alternative medications in clinical practice.
We will review current evidence addressing important knowledge gaps in the detection and treatment of neuropsychiatric symptoms in persons with dementia. At the end of this symposium, participants will be able to:
Understand which diagnostic tools are most accurate for detecting symptoms of anxiety, depression, agitation, and aggression in persons with dementia
-
Describe the comparative:
efficacy of pharmacologic and nonpharmacologic interventions for reducing symptoms of agitation, aggression, and depression in persons with dementia
safety (i.e. risk of fracture, falls, stroke, and death) of pharmacologic interventions for reducing neuropsychiatric in dementia
Facilitate evidence-based shared decision-making with patients and caregivers using a tool (i.e. rank-heat plot) that ranks the comparative efficacy of pharmacologic and nonpharmacologic interventions across multiple treatment choices and outcomes of interest (i.e. agitation, aggression, depression, fractures, falls, stroke, and death)